Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:YSB YS Biopharma (YSB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisHeadlinesOwnershipTrends About YS Biopharma Stock (NASDAQ:YSB) 30 days 90 days 365 days Advanced Chart Remove Ads Get YS Biopharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.40▼$6.8252-Week Range N/AVolume63,510 shsAverage Volume172,401 shsMarket Capitalization$344.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewYS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.Read More… Remove Ads Receive YSB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for YS Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address YSB Stock News HeadlinesLakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share ConsolidationOctober 3, 2024 | finanznachrichten.deLakeShore Biopharma Co Ltd Ordinary Shares LSBAugust 17, 2024 | morningstar.comWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin says stocks could crash in 2026—he's even calling the exact month and most likely day it will start. No one on or off Wall Street has been more accurate calling the bull and bear turns of the past 7 years. And now, Chaikin is calling the crash of 2026.March 12, 2025 | Chaikin Analytics (Ad)LSB LakeShore Biopharma Co., LtdJuly 20, 2024 | seekingalpha.comPieris Pharmaceuticals (NASDAQ:PIRS) Stock Quotes, Forecast and News SummaryJuly 19, 2024 | benzinga.comYS Biopharma Co., Ltd.: YS Biopharma Announces Name Change to LakeShore BiopharmaMay 24, 2024 | finanznachrichten.deYS Biopharma Announces Name Change to LakeShore BiopharmaMay 24, 2024 | prnewswire.comYS Biopharma Co., Ltd.: YS Biopharma Announces Results of Extraordinary General MeetingMay 22, 2024 | finanznachrichten.deSee More Headlines Company Calendar Today3/12/2025Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:YSB Previous SymbolNASDAQ:YS CIK1946399 Webwww.ysbiopharm.com Phone852-2155-7212FaxN/AEmployees773Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.26 Current Ratio0.94 Quick Ratio0.73 Sales & Book Value Annual Sales$560.76 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.14 per share Price / BookN/AMiscellaneous Outstanding Shares93,058,000Free FloatN/AMarket Cap$344.32 million OptionableNot Optionable Beta0.51 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:YSB) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersFormer CIA to Trump – Will you Shut down this secret lab?Deep in the sands of New Mexico lies a government lab so secret it makes Area 51 look like a tourist spot… ...Paradigm Press | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredMarch 18th: Gold SHOCK? On March 18th, an event is taking place that could completely shock the market. Stocks could go ballistic…...InvestorPlace | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredMusk’s real agenda in Washington… In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | SponsoredDeFi Coin on Verge of Breakout!We’re Opening the Ultimate Crypto Vault… Don't let this be the missed opportunity you regret for years. Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding YS Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share YS Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.